(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Comprehend and Use Open Record Extra Offers - 2Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained
- 3Explainer-Why are hepatitis B vaccines given to newborns?
- 4The powerful new Rubin Observatory just found 11,000 new asteroids and measured 'tens of thousands more'
- 5Instructions to Warmly greet Discretion and Thoughtfulness
- The Green Transformation: 5 Feasible Living Practices
- Choosing the Ideal Bed for Quality Rest and Solace
- Which Carrier Do You Suggest? Vote
- This star-forming galaxy is blowing out powerful winds topping 2 million mph
- Exploring the Difficulties of Beginning a Family: Individual Experiences
- Must-See Attractions in France
- Israel strikes Iranian nuclear development facilities, Tehran vows retaliation
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
